Not found

Antonio Gotto, MD, DPhil

Full Member, Research Institute
Professor of Medicine, Provost for Medical Affairs & Dean Emeritus, Weill Cornell Medical College
Houston Methodist
Weill Cornell Medical College


Dr. Antonio M. Gotto is the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College in New York, New York, where he is also Professor of Medicine. In addition, Dr. Gotto is Provost for Medical Affairs of Cornell University. He joined Houston Methodist Research Institute in 2011. Previously, at Baylor College of Medicine in Houston, Texas, he was the Bob and Vivian Smith Professor and Chairman of the Department of Medicine, Scientific Director of the DeBakey Heart Center, and the JS Abercrombie Chair for Atherosclerosis and Lipoprotein Research. He also served as Chief of the Internal Medicine Service at The Methodist Hospital in Houston. Dr. Gotto's postgraduate work included doctoral studies at Oxford University in England as a Rhodes Scholar, and residency training at the Massachusetts General Hospital in Boston, Massachusetts.

As a lifelong supporter of educational efforts aimed at cardiovascular risk reduction, Dr. Gotto has been National President of the American Heart Association and President of the International Atherosclerosis Society. He is a member of the Institute of Medicine and the American Academy of Arts and Sciences and a recipient of many honors, including the Gold Heart Award from the American Heart Association, the 2000 Distinguished Alumnus award from Vanderbilt University and the Vanderbilt University School of Medicine, honorary doctoral degrees from the University of Bologna and Abilene Christian University, honorary professorships from the University of Buenos Aires and Francisco Marroquin University (Guatemala), and the Order of the Lion from the Republic of Finland. Dr. Gotto was the 2004 recipient of the International Okamoto Award from the Japan Vascular Disease Research Foundation. In 2004 Dr. Gotto was also named Honorary Member of the Society for Progress in Internal Medicine (Ludwig Heilmeyer Society) in Germany. In 2010, he received the Maurice R. Greenberg Distinguished Service Award, the highest honor bestowed by New York-Presbyterian/Weill Cornell on members of the medical staff.

Dr. Gotto speaks nationally and internationally on cardiovascular disease and has contributed more than 500 scholarly articles and books to the medical literature. In addition, he is coauthor of a series of books that explain the origins and treatment of cardiovascular disease to the general public.

Description of Research

In the field of atherosclerosis, his basic science research interests include clinical disorders of lipid transport and the structure, metabolism, and function of lipoproteins and apolipoproteins. He and his associates were the first to achieve complete synthesis of a plasma apolipoprotein (apo C-I); they also determined the complete cDNA and amino acid sequence of apo B-100, one of the largest proteins ever sequenced and a key protein in atherosclerosis. In addition, Dr. Gotto has played a leading role in several landmark clinical trials demonstrating that cholesterol-lowering drug treatment can reduce the risk of heart disease.

Areas Of Expertise

Lipoproteins and apolipoproteins Atherosclerosis Lipid metabolism Statins
Education & Training

, University of Oxford

Acylation of lysine residues in human plasma high density lipoprotein increases stability and plasma clearance in vivo
Yang, Y, Rosales, C, Gillard, BK, Gotto, AM & Pownall, HJ 2016, Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, vol 1861, no. 11, pp. 1787-1795. DOI:

Pitavastatin differentially modulates MicroRNA-Associated cholesterol transport proteins in macrophages
Zhang, H, Lamon, BD, Moran, G, Sun, T, Gotto, AM & Hajjar, DP 2016, PLoS ONE, vol 11, no. 7, e0159130. DOI:

Speciated High-Density Lipoprotein Biogenesis and Functionality
Rosales, C, Davidson, WS, Gillard, BK, Gotto, AM & Pownall, HJ 2016, Current Atherosclerosis Reports, vol 18, no. 5, 25. DOI:

Streptococcal serum opacity factor promotes cholesterol ester metabolism and bile acid secretion in vitro and in vivo
Gillard, BK, Rodriguez, PJ, Fields, DW, Raya, JL, Lagor, WR, Rosales, C, Courtney, HS, Gotto, AM & Pownall, HJ 2016, Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, vol 1861, no. 3, pp. 196-204. DOI:

Integrated Measure for Atherogenic Lipoproteins in the Modern Era Risk Assessment Based on Apolipoprotein B
Rosenson, RS, Hegele, RA & Gotto, AM 2016, Journal of the American College of Cardiology, vol 67, no. 2, pp. 202-204. DOI:

New Insights into the High-Density Lipoprotein Dilemma
Pownall, HJ & Gotto, AM 2016, Trends in Endocrinology and Metabolism, vol 27, no. 1, pp. 44-53. DOI:

High-Density Lipoprotein Processing and Premature Cardiovascular Disease
Rosales, C , Gillard, BK , Gotto, AM & Pownall, HJ 2015, Methodist DeBakey Cardiovascular Journal, vol 11, no. 3, pp. 181-5. DOI:

Statin Intolerance: the Clinician’s Perspective
Stulc, T, Ceška, R & Gotto, AM 2015, Current Atherosclerosis Reports, vol 17, no. 12, 69. DOI:

The low-density lipoprotein hypothesis: Proven again with the Improved Reduction of Outcomes: Vytorin Efficacy International Trial
Gotto, AM 2015, Journal of Clinical Lipidology, vol 9, no. 4, pp. 496-497. DOI:

Apolipoprotein AI deficiency inhibits serum opacity factor activity against plasma high density lipoprotein via a stabilization mechanism
Rosales, C, Patel, N, Gillard, BK, Yelamanchili, D, Yang, Y, Courtney, HS, Santos, RD, Gotto, AM & Pownall, HJ 2015, Biochemistry, vol 54, no. 14, pp. 2295-2302. DOI:

Optimizing statin treatment
Gotto, AM 2015, Trends in Cardiovascular Medicine, vol 25, no. 3, pp. 226-227. DOI:

Alcohol: a nutrient with multiple salutary effects
Pownall, HJ , Rosales, C , Gillard, BK & Gotto, AM 2015, Nutrients, vol 7, no. 3, pp. 1992-2000. DOI:

Alcohol: A nutrient with multiple salutary effects
Pownall, HJ , Rosales, C , Gillard, BK & Gotto, AM 2015, Nutrients, vol 7, no. 3, pp. 1992-2000. DOI:

Twenty-five years of statins: Where do we go from here?
Gotto, AM & Moon, JE 2015, Clinical Lipidology, vol 10, no. 1, pp. 33-45. DOI:

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: Evidence from genetic analysis and randomised trials
Swerdlow, DI, Preiss, D, Kuchenbaecker, KB, Holmes, MV, Engmann, JEL, Shah, T, Sofat, R, Stender, S, Johnson, PCD, Scott, RA, Leusink, M, Verweij, N, Sharp, SJ, Guo, Y, Giambartolomei, C, Chung, C, Peasey, A, Amuzu, A, Li, K, Palmen, J, Howard, P, Cooper, JA, Drenos, F, Li, YR, Lowe, G, Gallacher, J, Stewart, MCW, Tzoulaki, I, Buxbaum, SG, Van Der A, DL, Forouhi, NG, Onland-Moret, NC, Van Der Schouw, YT, Schnabel, RB, Hubacek, JA, Kubinova, R, Baceviciene, M, Tamosiunas, A, Pajak, A, Topor-Madry, R, Stepaniak, U, Malyutina, S, Baldassarre, D, Sennblad, B, Tremoli, E, De Faire, U, Veglia, F, Ford, I, Jukema, JW, Westendorp, RGJ, De Borst, GJ, De Jong, PA, Algra, A, Spiering, W, Der Zee, AHMV, Klungel, OH, De Boer, A, Doevendans, PA, Eaton, CB, Robinson, JG, Duggan, D, Kjekshus, J, Downs, JR, Gotto, AM, Keech, AC, Marchioli, R, Tognoni, G, Sever, PS, Poulter, NR, Waters, DD, Pedersen, TR, Amarenco, P, Nakamura, H, McMurray, JJV, Lewsey, JD, Chasman, DI, Ridker, PM, Maggioni, AP, Tavazzi, L, Ray, KK, Seshasai, SRK, Manson, JE, Price, JF, Whincup, PH, Morris, RW, Lawlor, DA, Smith, GD, Ben-Shlomo, Y, Schreiner, PJ, Fornage, M, Siscovick, DS, Cushman, M, Kumari, M, Wareham, NJ, Verschuren, WMM, Redline, S, Patel, SR, Whittaker, JC, Hamsten, A, Delaney, JA, Dale, C, Gaunt, TR, Wong, A, Kuh, D, Hardy, R, Kathiresan, S, Castillo, BA, Van Der Harst, P, Brunner, EJ, Tybjaerg-Hansen, A, Marmot, MG, Krauss, RM, Tsai, M, Coresh, J, Hoogeveen, RC, Psaty, BM, Lange, LA, Hakonarson, H, Dudbridge, F, Humphries, SE, Talmud, PJ, Kivimäki, M, Timpson, NJ, Langenberg, C, Asselbergs, FW, Voevoda, M, Bobak, M, Pikhart, H, Wilson, JG, Reiner, AP, Keating, BJ, Hingorani, AD & Sattar, N 2015, The Lancet, vol 385, no. 9965, pp. 351-361. DOI:

The effect of statin therapy on heart failure events: A collaborative meta-analysis of unpublished data from major randomized trials
Preiss, D, Campbell, RT, Murray, HM, Ford, I, Packard, CJ, Sattar, N, Rahimi, K, Colhoun, HM, Waters, DD, LaRosa, JC, Amarenco, P, Pedersen, TR, Tikkanen, MJ, Koren, MJ, Poulter, NR, Sever, PS, Ridker, PM, MacFadyen, JG, Solomon, SD, Davis, BR, Simpson, LM, Nakamura, H, Mizuno, K, Marfisi, RM, Marchioli, R, Tognoni, G, Athyros, VG, Ray, KK, Gotto, AM, Clearfield, MB, Downs, JR & McMurray, JJ 2015, European Heart Journal, vol 36, no. 24, pp. 1536-1546. DOI:

Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174 000 participants in 27 randomised trials
Fulcher, J, OConnell, R, Voysey, M, Emberson, J, Blackwell, L, Mihaylova, B, Simes, J, Collins, R, Kirby, A, Colhoun, H, Braunwald, E, La Rosa, J, Pedersen, TR, Tonkin, A, Davis, B, Sleight, P, Franzosi, MG, Baigent, C, Keech, A, De Lemos, J, Braunwald, E, Blazing, M, Murphy, S, Downs, JR, Gotto, A, Clearfield, M, Holdaas, H, Gordon, D, Davis, B, Koren, M, Dahlöf, B, Poulter, N, Sever, P, Knopp, RH, Fellström, B, Holdaas, H, Jardine, A, Schmieder, R, Zannad, F, Goldbourt, U, Kaplinsky, E, Colhoun, HM, Betteridge, DJ, Durrington, PN, Hitman, GA, Fuller, J, Neil, A, Wanner, C, Krane, V, Sacks, F, Moyé, L, Pfeffer, M, Hawkins, CM, Braunwald, E, Kjekshus, J, Wedel, H, Wikstrand, J, Barter, P, Keech, A, Tavazzi, L, Maggioni, A, Marchioli, R, Tognoni, G, Franzosi, MG, Maggioni, A, Bloomfield, H, Robins, S, Collins, R, Armitage, J, Keech, A, Parish, S, Peto, R, Sleight, P, Pedersen, TR, Ridker, PM, Holman, R, Meade, T, Simes, J, Keech, A, MacMahon, S, Marschner, I, Tonkin, A, Shaw, J, Serruys, PW, Nakamura, H, Knatterud, G, Furberg, C, Byington, R, Macfarlane, P, Cobbe, S, Ford, I, Murphy, M, Blauw, GJ, Packard, C, Shepherd, J, Kjekshus, J, Pedersen, T, Wilhelmsen, L, Braunwald, E, Cannon, C, Murphy, S, Collins, R, Armitage, J, Bowman, L, Parish, S, Peto, R, Sleight, P, Baigent, C, Landray, M, Collins, R, La Rosa, J, Rossouw, J, Probstfield, J, Shepherd, J, Cobbe, S, Macfarlane, P, Ford, I, Flather, M, Kastelein, J, Newman, C, Shear, C, Tobert, J, Varigos, J, White, H, Yusuf, S, Barnes, EH, Keech, AC, Kirby, A, Marschner, IC, Simes, J, Baigent, C, Blackwell, L, Collins, R, Emberson, J, Herrington, WG, Holland, LE, Mihaylova, B & Reith, C 2015, The Lancet, vol 385, no. 9976, pp. 1397-1405. DOI:

Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the efficacy and tolerability of CETP INhibition with AnacEtrapib) trial
Brinton, EA, Kher, U, Shah, S, Cannon, CP, Davidson, M, Gotto, AM, Ashraf, TB, Sisk, CM, Dansky, H, Mitchel, Y, Barter, P & DEFINE Investigators, I 2015, Journal of Clinical Lipidology, vol 9, no. 1, pp. 65-71. DOI:

Statins: Risk-benefits and role in treating dyslipidemias
Gotto, AM & Moon, JE 2015, . in Dyslipidemias: Pathophysiology, Evaluation and Management. Humana Press Inc. pp. 403-421. DOI:

Prevention and treatment of atherosclerotic vascular disease: Hypolipidemic agents
Gotto, AM & Pownall, HJ 2015, . in Pathophysiology and Pharmacotherapy of Cardiovascular Disease. Springer International Publishing, pp. 589-611. DOI: